Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Russia
Approved Indications: None
Known Adverse Events: None
Company: R-Pharm
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatitis A|Hepatitis C, Chronic
Phase 2: Hepatitis C, Chronic|Hepatitis A
Phase 1: Hepatitis C, Chronic|Liver Cirrhosis|Cross Infection|Coinfection
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CJ05013053 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2020-04-08 |
43% |
| CJ05013046 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2018-08-29 |
26% |
| CJ05013019 | P1 |
Completed |
Cross Infection|Hepatitis C, Chronic|Coinfection |
2017-06-24 |
|
| PIONEER | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2016-03-23 |
|
| CJ05013007 | P1 |
Completed |
Liver Cirrhosis |
2014-10-24 |
|
| P05063 | P3 |
Terminated |
Hepatitis C, Chronic|Hepatitis A |
2014-10-13 |
|
| Protocol No. P04695 | P1 |
Completed |
Hepatitis C, Chronic |
2008-08-01 |